Lab
Spectra Laboratories INC
Spectra Laboratories INC was paid $6.19M by Medicaid between Aug 2021 and Dec 2024, across 89 billing codes. Its largest line is 83970, — 30% of everything it billed.
33Billing provider infoSPECTRA LABORATORIES INC
SOUTHAVEN, MS 38671
SOUTHAVEN, MS 38671
33aNPI1396321022assigned 03/23/2021
33bProvider typeClinical Medical Laboratory
28Total paid$6.19M
24GClaims795,164
24DCodes billed89
24AFirst – last monthAug 2021 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Mississippi
Rank by total paid#1 of 35
Median peer was paid$136K
This provider vs. median46×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 45,070 | $281K | |
| 2022 | 246,383 | $2.00M | |
| 2023 | 295,953 | $2.44M | |
| 2024incomplete | 207,758 | $1.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 83970 | 30% | 55,144 | 48,439 | $1.86M | |
| 83550 | 7.9% | 71,580 | 64,673 | $489K | |
| 82728 | 7.3% | 42,761 | 38,736 | $450K | |
| 83540 | 6.2% | 73,469 | 66,792 | $382K | |
| 87340 | 5.6% | 44,796 | 40,251 | $344K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.2% | 13,759 | 12,614 | $324K |
| 84295 | 2.6% | 35,357 | 32,751 | $161K | |
| 82108 | 2.3% | 9,286 | 8,092 | $145K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.3% | 45,059 | 40,790 | $141K |
| 86706 | 2.0% | 15,848 | 14,081 | $124K | |
| 85018 | 2.0% | 61,063 | 20,695 | $123K | |
| 83735 | 1.9% | 20,886 | 19,228 | $116K |
77 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 15,724 | $105K |
| 82947 | 1.6% | 29,215 | $100K | |
| 85046 | 1.6% | 19,853 | $98K | |
| 84132 | 1.6% | 26,780 | $98K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 2,405 | $84K |
| 86803 | 1.2% | 10,165 | $76K | |
| 82310 | 1.1% | 16,983 | $67K | |
| 84466 | 1.1% | 6,456 | $66K | |
| 84100 | 1.1% | 18,273 | $66K | |
| 84460 | 1.0% | 13,942 | $64K | |
| 82040 | <1% | 15,722 | $60K | |
| 82746 | <1% | 5,937 | $57K | |
| 86704 | <1% | 6,739 | $54K | |
| 84520 | <1% | 18,406 | $51K | |
| 80050 | General health panel | <1% | 773 | $50K |
| 80061 | Lipid panel | <1% | 7,484 | $41K |
| 80051 | <1% | 6,722 | $38K | |
| 82607 | <1% | 3,855 | $38K | |
| 80069 | <1% | 4,615 | $32K | |
| 85027 | <1% | 6,328 | $26K | |
| 82565 | <1% | 6,281 | $25K | |
| 84155 | <1% | 7,975 | $23K | |
| 84134 | <1% | 1,313 | $20K | |
| 85045 | <1% | 5,852 | $17K | |
| 84075 | <1% | 4,410 | $17K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,426 | $14K |
| 82247 | <1% | 2,959 | $13K | |
| 87040 | <1% | 1,752 | $12K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,543 | $12K |
| 80202 | <1% | 3,442 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 386 | $10K |
| 83718 | <1% | 1,441 | $8K | |
| 82374 | <1% | 1,960 | $8K | |
| 84540 | <1% | 2,067 | $7K | |
| 82570 | <1% | 1,940 | $7K | |
| 84450 | <1% | 1,867 | $6K | |
| 83615 | <1% | 2,813 | $4K | |
| 87186 | <1% | 1,710 | $4K | |
| 85014 | <1% | 2,514 | $4K | |
| 82435 | <1% | 1,022 | $3K | |
| 87070 | <1% | 669 | $3K | |
| 84550 | <1% | 1,447 | $3K | |
| 82652 | <1% | 75 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 144 | $2K |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | <1% | 351 | $2K |
| 85004 | <1% | 286 | $2K | |
| 82248 | <1% | 446 | $2K | |
| 87205 | <1% | 1,300 | $2K | |
| 87147 | <1% | 940 | $1K | |
| 85049 | <1% | 321 | $1K | |
| 85610 | <1% | 1,576 | $1K | |
| 86703 | <1% | 330 | $1K | |
| 82330 | <1% | 75 | $1K | |
| 86140 | <1% | 1,438 | $1K | |
| 87075 | <1% | 166 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 168 | $994.76 |
| 85048 | <1% | 454 | $980.55 | |
| 82977 | <1% | 430 | $964.65 | |
| 85041 | <1% | 315 | $899.83 | |
| 82465 | <1% | 654 | $850.63 | |
| 87077 | <1% | 131 | $786.25 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 32 | $618.86 |
| 89051 | <1% | 562 | $603.54 | |
| 84478 | <1% | 266 | $551.81 | |
| 85651 | <1% | 525 | $518.81 | |
| 80053 | Comprehensive metabolic panel | <1% | 33 | $256.50 |
| 87081 | <1% | 119 | $193.62 | |
| 83721 | <1% | 46 | $175.14 | |
| 89050 | <1% | 231 | $159.67 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 85 | $85.64 |
| 86705 | <1% | 12 | $83.79 | |
| 82272 | <1% | 104 | $68.48 | |
| 82945 | <1% | 133 | $59.47 | |
| 84439 | <1% | 16 | $35.02 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 51 | $0.00 |
| 83090 | 0% | 140 | $0.00 | |
| 84153 | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRYDER, ALEX (SENIOR VP AND MEDICAL DIRECTOR)